Lupin closes VISUfarma deal, but can branded ophthalmology drive the next phase of growth?
Lupin has completed its VISUfarma acquisition. Read what the deal changes for European ophthalmology, specialty pharma growth, and execution risk.
Can smaller eyedrops improve glaucoma outcomes? Nanodropper data make the case
Nanodropper’s glaucoma study suggests microdrops may improve pressure control and reduce waste. Read what this could mean for eye care.